Core Viewpoint - The company expects a significant increase in net profit for the period from January 1, 2025, to June 30, 2025, projecting a net profit attributable to shareholders of 3.3 billion to 3.75 billion yuan, representing a growth of 50% to 70% compared to the same period last year [1] Financial Performance - The net profit excluding non-recurring gains and losses is projected to be between 3.25 billion and 3.7 billion yuan, which indicates a growth of 51% to 71% year-on-year [1] - The basic earnings per share are estimated to be between 1.07 yuan and 1.22 yuan [1] Business Segment Performance - The nutrition product segment has seen an increase in both sales volume and sales prices compared to the same period last year, contributing to the overall improvement in operating performance [1]

[Current Period Performance Forecast](index=1&type=section&id=Current%20Period%20Performance%20Forecast) The company forecasts a significant year-over-year increase in net profit and earnings per share for the first half of 2025 [Performance Forecast Period](index=1&type=section&id=Performance%20Forecast%20Period) This performance forecast covers the period from January 1, 2025, to June 30, 2025 - The performance forecast period is **January 1, 2025, to June 30, 2025**[3](index=3&type=chunk) [Estimated Performance](index=1&type=section&id=Estimated%20Performance) The company expects net profit attributable to shareholders and net profit after non-recurring gains/losses to increase by over 50% year-over-year for H1 2025, with basic earnings per share also significantly rising - The company anticipates a **year-over-year increase** in performance for the current reporting period[3](index=3&type=chunk) H1 2025 Performance Forecast | Item | Current Period Forecast (10,000 CNY) | Year-over-Year Growth | Prior Period (10,000 CNY) | | :--------------------------------- | :--------------------------- | :-------------------- | :------------------------ | | Net Profit Attributable to Shareholders | 330,000—375,000 | 50%—70% | 220,436 | | Net Profit After Non-Recurring Items | 325,000—370,000 | 51%—71% | 215,746 | | Basic Earnings Per Share (CNY/share) | 1.07—1.22 | - | 0.71 | [Communication with Accounting Firm](index=1&type=section&id=Communication%20with%20Accounting%20Firm) The financial data presented in this performance forecast has not been audited by a certified public accountant [Audit Status Explanation](index=1&type=section&id=Audit%20Status%20Explanation) The financial data involved in this performance forecast has not been audited by a certified public accountant - The financial data related to this performance forecast has **not been audited** by a certified public accountant[4](index=4&type=chunk) [Explanation of Performance Changes](index=1&type=section&id=Explanation%20of%20Performance%20Changes) The company's performance growth is primarily attributed to increased sales volume and prices of key nutritional products during the reporting period [Drivers of Performance Growth](index=1&type=section&id=Drivers%20of%20Performance%20Growth) During the reporting period, both sales volume and sales prices of the company's main nutritional products increased year-over-year, driving improved operating performance - During the reporting period, both **sales volume and sales prices** of key nutritional products increased year-over-year[5](index=5&type=chunk) - The simultaneous increase in sales volume and price was the primary reason for the **improvement in operating performance**[5](index=5&type=chunk) [Risk Warning](index=1&type=section&id=Risk%20Warning) This performance forecast is a preliminary estimate, and investors are advised to consider investment risks as final data will be in the H1 2025 report [Limitations of Performance Forecast and Investment Risks](index=1&type=section&id=Limitations%20of%20Performance%20Forecast%20and%20Investment%20Risks) This performance forecast represents preliminary estimates by the company's finance department, with final financial data subject to the 2025 semi-annual report, urging investors to be aware of investment risks - This performance forecast is a **preliminary estimate** by the company's finance department[6](index=6&type=chunk) - The definitive financial data will be based on the **company's 2025 semi-annual report**[6](index=6&type=chunk) - Investors are kindly advised to **exercise caution regarding investment risks**[6](index=6&type=chunk)

Group 1 - The core index, the China Securities Zhejiang Phoenix Action 50 Index (Phoenix 50), increased by 0.6% to 6186.75 points, with a trading volume of 16.109 billion yuan [1] - The Phoenix 50 index has shown a growth of 3.22% over the past month, 2.36% over the past three months, and 6.16% year-to-date [1] - The index comprises 50 securities selected from profitable and high-dividend companies listed in Zhejiang Province, reflecting the overall performance of high-dividend and high-growth stocks in the region [1] Group 2 - The top ten holdings of the Phoenix 50 index include: Hangzhou Bank (10.03%), Hikvision (9.6%), Huayou Cobalt (8.93%), Xinhongcheng (5.79%), Dahua Technology (5.57%), China Jushi (4.85%), Tianshan Aluminum (4.11%), Changchuan Technology (3.51%), Deyang Co. (3.38%), and Wuchan Zhongda (2.91%) [1] - The index's market composition shows that 55.76% of the holdings are from the Shenzhen Stock Exchange, while 44.24% are from the Shanghai Stock Exchange [1] Group 3 - The industry composition of the index includes: Materials (25.39%), Information Technology (18.98%), Industrials (13.69%), Financials (12.04%), Consumer Discretionary (11.96%), Health Care (9.78%), Communication Services (5.49%), Consumer Staples (1.77%), Utilities (0.74%), and Real Estate (0.17%) [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - Public funds tracking the Phoenix 50 include: Zhejiang Merchants Huijin China Securities Phoenix 50 ETF Link A, Zhejiang Merchants Huijin China Securities Phoenix 50 ETF Link C, and Zhejiang Merchants Huijin China Securities Phoenix 50 ETF [2]

证券代码：002001 证券简称：新和成 公告编号：2025-035 浙江新和成股份有限公司 关于回购公司股份进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新和成股份有限公司（以下简称"公司"）于2025年4月11日召开的第 九届董事会第十一次会议审议通过《关于回购公司股份方案的议案》，同意公司 使用自有资金或回购专项贷款以集中竞价交易的方式回购公司部分社会公众股 份，用于实施股权激励计划或员工持股计划。本次回购金额区间为30,000万元- 60,000万元，回购价格不超过人民币32元/股，具体回购股份的数量及占总股本的 比例以回购期满时实际回购数量为准。本次回购股份的实施期限为自公司董事会 审议通过回购股份方案之日起不超过12个月。 根据公司披露的《关于回购公司股份方案的公告》《回购股份报告书》（公告 编号：2025-010、2025-023）相关规定，若公司在回购期间内发生资本公积转增 股本、派发红利、送红股等除权除息事宜，自股价除权除息之日起，按照中国证 监会及深圳证券交易所的相关规定相应调整回购价格。公司 2025 年 5 月 21 ...

Group 1: Production and Sales - The company has an annual production capacity of 300,000 tons for solid methionine, with a high utilization rate and strong sales performance [2][3] - The liquid methionine project in cooperation with Sinopec, with a capacity of 180,000 tons, has entered the trial production phase and has successfully produced qualified products [3] Group 2: Fragrance and Flavor Products - The fragrance segment includes products such as linalool, citral, and menthol, widely used in personal care, household care, cosmetics, and food [3] - The company is focusing on optimizing product structure and expanding its fragrance product range to enhance core competitiveness [3][4] Group 3: New Materials Sector - The new materials sector is seen as having significant market potential, with a focus on high-performance polymers and key intermediates [3][4] - The Tianjin nylon new materials project is currently in the approval stage, with environmental assessments completed [4] Group 4: Biological Fermentation Products - The Heilongjiang base is focused on biological fermentation products, including Vitamin C and various amino acids, with efforts to improve efficiency and expand the product line [4] - The base aims to develop new products through a technology-first approach, enhancing synergy with existing business segments [4] Group 5: Employee Incentives and Shareholder Returns - The company has completed its employee stock ownership plan and is considering future equity incentive methods to attract talent [4][5] - Since its listing, the company has distributed a total of 15.5 billion yuan in dividends, representing 30%-50% of annual net profits, and is actively repurchasing shares within a range of 300 million to 600 million yuan [5]

关于第四期员工持股计划出售完毕暨终止的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新和成股份有限公司（以下简称"公司"）于2023年6月7日召开第八届 董事会第十六次会议、第八届监事会第十三次会议，于2023年6月26日召开2023 年第一次临时股东大会，审议通过《浙江新和成股份有限公司第四期员工持股计 划（草案）及其摘要》等员工持股计划相关议案，同意公司实施第四期员工持股 计划。具体内容详见公司于2023年6月8日、2023年6月27日在指定信息披露媒体 及巨潮资讯网（http://www.cninfo.com.cn）上刊登的公告。 截至本公告日，公司第四期员工持股计划持有的公司股票已全部出售完毕。 根据相关规定，第四期员工持股计划已实施完毕并终止，后续将进行相关资产清 算和分配等工作。 特此公告。 证券代码：002001 证券简称：新和成 公告编号：2025-034 浙江新和成股份有限公司 浙江新和成股份有限公司董事会 2025年6月26日 ...

Core Insights - The report highlights the rapid growth of the company, with 2024 revenue reaching 21.61 billion yuan, a year-on-year increase of 42.95%, and net profit attributable to shareholders at 5.87 billion yuan, up 117.01% [2][5][6] - The company plans to distribute a cash dividend of 5.00 yuan per 10 shares to all shareholders [2][5] - The nutritional products segment saw significant growth, with revenue of 15.06 billion yuan in 2024, a 52.58% increase year-on-year, driven by the release of new production capacity and recovery in the downstream aquaculture industry [7][8] Financial Performance - In Q4 2024, the company achieved revenue of 5.83 billion yuan, a 41.99% increase year-on-year, but a slight decrease of 1.84% quarter-on-quarter [2][5] - For Q1 2025, revenue was 5.44 billion yuan, a 20.91% increase year-on-year, but a 6.66% decrease quarter-on-quarter [2][5] - The gross margin for 2024 was 41.78%, up 8.80 percentage points year-on-year, while the net margin was 27.29%, an increase of 9.26 percentage points [6] Product and Market Insights - The average price of key products in the nutritional segment increased significantly in 2024, with VA averaging 133.48 yuan/kg (up 58.12%), VE at 100.84 yuan/kg (up 42.82%), and methionine at 20.90 yuan/kg (up 19.25%) [7] - The company has successfully released 300,000 tons/year of methionine production capacity and is progressing on a joint venture project with Sinopec for an 180,000 tons/year liquid methionine project [7][8] Project Development - The company is actively advancing new projects in flavors and fragrances, new materials, and active pharmaceutical ingredients, with the flavors and fragrances segment generating revenue of 3.92 billion yuan in 2024, a 19.62% increase [8] - The new materials segment achieved revenue of 1.68 billion yuan, a 39.51% increase, with ongoing development in PPS applications and nylon new materials [8]

Investment Rating - The report maintains a "Buy" rating for the company, with a market price of RMB 21.70 and a sector rating of "Outperform" [2][5]. Core Insights - The company has experienced rapid growth in performance, particularly in the methionine and new materials sectors, with orderly capacity release and ongoing project construction [5][10]. - For 2024, the company achieved a revenue of RMB 21.61 billion, a year-on-year increase of 42.95%, and a net profit attributable to shareholders of RMB 5.87 billion, up 117.01% year-on-year [5][11]. - The first quarter of 2025 saw a revenue of RMB 5.44 billion, reflecting a 20.91% year-on-year growth, and a net profit of RMB 1.88 billion, which is a 116.18% increase year-on-year [5][13]. Financial Performance Summary - The company’s revenue and net profit for 2024 were significantly boosted by the sales and price increases of key products in the nutrition segment, alongside effective cost management [10][11]. - The gross margin for 2024 was 41.78%, an increase of 8.80 percentage points year-on-year, while the net margin reached 27.29%, up 9.26 percentage points year-on-year [10]. - The company plans to distribute a cash dividend of RMB 5.00 per 10 shares to all shareholders [5]. Earnings Forecast - The earnings forecast for 2025-2027 projects net profits of RMB 64.65 billion, RMB 74.16 billion, and RMB 79.25 billion respectively, with corresponding earnings per share of RMB 2.10, RMB 2.41, and RMB 2.58 [7][15]. - The report anticipates a price-to-earnings ratio of 10.3, 9.0, and 8.4 for the years 2025, 2026, and 2027 respectively [7][15]. Shareholder Information - The major shareholder is Xinhengcheng Holdings Group Co., Ltd., holding 50.08% of the company [10].

证券代码：002001 证券简称：新和成 公告编号：2025-033 浙江新和成股份有限公司 关于董事、董事会秘书增持公司股份结果的公告 公司董事、董事会秘书、副总裁、财务总监石观群先生保证向本公司提供的 信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 3、增持方式：二级市场集中竞价交易方式。 特别提示： 浙江新和成股份有限公司（以下简称"公司"）收到公司董事、董事会秘书、 副总裁、财务总监石观群先生的通知，获悉石观群先生于 2025 年 6 月 17 日通过 二级市场竞价交易方式增持公司股份 200,000 股，占公司总股本的 0.0065%。现 将本次增持股份结果公告如下： 一、增持主体的基本情况 1、增持主体：公司董事、董事会秘书、副总裁、财务总监石观群先生。 2、增持目的：基于对公司未来持续稳定发展的信心以及对公司价值的认可， 积极践行"质量回报双提升"行动方案，提振投资者信心，维护市场稳定。 2、石观群先生在本次增持前 12 个月内未披露过增持计划，在本次增持前 6 个月内不存在减持公司股份的情形。石观群先生将严格遵 ...

Core Viewpoint - The company is actively enhancing investor confidence and market stability through share buybacks and consistent dividend payments, while also focusing on strategic growth and innovation in the chemical and biological sectors [2][3][4]. Group 1: Shareholder Actions - The company's Vice President and CFO, Shi Guanqun, purchased 200,000 shares on June 17, increasing his direct holdings to approximately 10.68 million shares, representing 0.35% of the total share capital [2]. - The controlling shareholder, Xinhecheng Holdings Group, has consistently increased its stake in the company over the past three years, with a total investment of 687 million yuan [2]. - The company has a history of not reducing shareholdings, with commitments from major stakeholders to support market stability through continued share purchases [2]. Group 2: Financial Performance - Since the announcement of the "Quality Return Dual Improvement" action plan in March 2024, the company has seen significant growth, with revenue, total profit, and net profit attributable to shareholders increasing by 42.95%, 113.42%, and 117.01% year-on-year, respectively [2]. - The company has maintained a cash dividend policy since its listing, distributing 30%-50% of annual net profits as dividends, totaling 15.5 billion yuan since inception [3]. - In 2024, the company repurchased and canceled 17.49 million shares for 500 million yuan, with a new buyback plan of 300 million to 600 million yuan announced for 2025 [3]. Group 3: Future Strategy - The company plans to continue implementing the "Quality Return Dual Improvement" action plan, focusing on core business areas and strategic growth [4]. - The operational guiding principles for 2025 include accelerating market expansion, enhancing innovation, improving management capabilities, and maintaining stable operations to mitigate risks [4]. - The company aims to establish itself as "World Xinhecheng" by focusing on the "Chemicals+" and "Biological+" strategic pathways, emphasizing project construction and risk management [4].